Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer
Accurate Identification of Tumor Origin Using MicroRNAs is Published by Rosetta Genomics' Scientists and Collaborators in Nature Biotechnology
April 8th, 2008
Rosetta Genomics, Ltd. (NASDAQ: ROSG), announced that the results of a research study, conducted by its scientists and collaborators and describing the use of microRNAs in accurately identifying tumor origin, have been published in Nature Biotechnology. . The study findings demonstrate microRNAs' significant potential to act as effective biomarkers that may be applied in a diagnostic test designed to identify the primary tumor site in patients with cancer of unknown primary (CUP). Rosetta Genomics is currently developing a technology that will be the basis of a CUP diagnostic tests that will be submitted by a CLIA certified lab in the US in 2008.. "Accurately...
Source: Cancer Weekly (2008-04-08)
|
|
Advertisement |
|
|
|
